Company news
Ligand Pharmaceuticals Incorporated news in 2021
Ligand Pharmaceuticals Incorporated's news releases, calls and decks from 2021, newest first.
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
December 21, 2021
Ligand and GSK Expand Global Collaboration and License Agreement
December 20, 2021
Ligand Reports Third Quarter 2021 Financial Results
November 8, 2021
Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
November 8, 2021
Ligand to Report Third Quarter Financial Results on November 9, 2021
October 25, 2021
Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™
October 20, 2021
Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
August 29, 2021
Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
August 15, 2021
Ligand Reports Second Quarter 2021 Financial Results
July 28, 2021
Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458
July 20, 2021
Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
July 18, 2021
Ligand to Report Second Quarter Financial Results on July 29, 2021
July 15, 2021
Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors
July 13, 2021
GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement
June 1, 2021
Ligand Reports First Quarter 2021 Financial Results
May 2, 2021
Ligand to Report First Quarter Financial Results on May 3, 2021
April 21, 2021
Ligand Reports Fourth Quarter and Full Year 2020 Financial Results
February 2, 2021
Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
February 1, 2021
Ligand’s Fourth Quarter Financial Results to be Reported February 3rd
January 19, 2021
Ligand Receives Milestone Payment from Merck
January 12, 2021
Calls in 2021
- Ligand Pharmaceuticals (NASDAQ:LGND) Q3 2021 Earnings Call
Nov 9, 2021
Transcript - Ligand Pharmaceuticals (NASDAQ:LGND) Q2 2021 Earnings Call
Jul 29, 2021
Transcript - Ligand Pharmaceuticals (NASDAQ:LGND) Q1 2021 Earnings Call
May 3, 2021
Transcript - Ligand Pharmaceuticals (NASDAQ:LGND) Q4 2020 Earnings Call
Feb 3, 2021
Transcript